x Health Men's Health Children's Health Nutrition and Wellness Reproductive Health Health & Science Digital News Videos Opinions Cartoons Education E-Paper Lifestyle & Entertainment Nairobian Entertainment Eve Woman Travelog TV Stations KTN Home KTN News BTV KTN Farmers TV Radio Stations Radio Maisha Spice FM Vybez Radio Enterprise BULK SMS E-Learning Digger Classified The Standard Group Corporate Contact Us Rate Card Vacancies DCX O.M Portal Corporate Email RMS
Login ×
BTV
VAS
DCX
RMS

Gilead shares rise after United States approves remdesivir as COVID-19 drug

Health & Science - By Reuters | October 23rd 2020 at 07:57:20 GMT +0300
Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug remdesivir in patients with severe coronavirus disease (COVID-19), during the outbreak of the coronavirus disease (COVID-19), in Oceanside, California, U.S. [Reuters]

Shares of Gilead Sciences Inc rose 6% on Friday after its antiviral drug, remdesivir, became the first and only approved treatment for COVID-19 in the United States.

The U.S. health regulator’s approval on Thursday for its use in hospitalized patients came despite the World Health Organization last week saying the drug did not have a substantial effect on patients’ length of hospital stay or chances of survival in a global trial.

The U.S. Food and Drug Administration’s (FDA) backing signals its confidence in Gilead’s U.S.-based study results, which showed the drug was able to cut time to recovery in patients, Piper Sandler analyst Tyler Van Buren said in a client note.

Remdesivir has been available under an FDA emergency use authorization since May, after a study led by the National Institutes of Health showed it reduced hospital stays by five days.

The drug, given intravenously, could generate over $1 billion in sales during the second half of the year at the current case rate, analyst Van Buren said.

Covid 19 Time Series

 

Remdesivir, which will be sold under the brand name Veklury, costs $3,120 for a five-day treatment course, or $2,340 for government purchasers such as the Department of Veterans Affairs.

Shares of Gilead were up 5.67% at $64.11 before the bell.


Gilead Sciences Inc COVID-19

Top Stories

MP’s battle with Covid-19 at home
Health & Science - By Mercy Kahenda


Kenyans in US listed among top TB spreaders
Health & Science - By Gatonye Gathura


After weeping for doctors, Nyikal now defends his stint at MOH
Health & Science - By Japheth Ogila


Poor girls sell sex to get money for sanitary products
Reproductive Health - By Kirsten Kanja


Woman gives birth to 13-year old stone baby
Health & Science - By Anyango Atieno


The toughest 9 months: I was pregnant with cancer
Reproductive Health - By Jeckonia Otieno


You have deserted us, health unions say
Health & Science - By Grace Ng'ang'a


Kidney specialist Dr Were succumbs to Covid-19
Health & Science - By Mireri Junior


University lecturer Dr Ken Ouko is dead
Health & Science - By Mireri Junior


Coming soon: Use of saliva for Covid-19 testing
Health & Science - By Killiad Sinide


Latest Stories

You have deserted us, health unions say
Health & Science - By Grace Ng'ang'a


MP’s battle with Covid-19 at home
Health & Science - By Mercy Kahenda


World's top surgical glove maker shuts factories due to coronavirus
Health & Science - By AFP


Covid-19:12 more die as Kenya records 413 new cases
Health & Science - By Mireri Junior


Clinical officers issue strike notice over PPE
Health & Science - By Mercy Kahenda


Coming soon: Use of saliva for Covid-19 testing
Health & Science - By Killiad Sinide


MPs want Covid-19 essentials zero rated
Health & Science - By Graham Kajilwa


After weeping for doctors, Nyikal now defends his stint at MOH
Health & Science - By Japheth Ogila


Our clotting disease triggered by the sun
Health & Science - By Mactilda Mbenywe


Kenyans in US listed among top TB spreaders
Health & Science - By Gatonye Gathura


//

Stay Ahead!

Access premium content only available
to our subscribers.

Support independent journalism
×
Log in
Support independent journalism
Create an account    Forgot Password
Create An Account
Support independent journalism
I have an account Log in
Reset Password
Support independent journalism
Log in